Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation beams target dangerous heart rhythms

NCT ID NCT05696522

NEW Symptom relief Sponsor: Barts & The London NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Ventricular tachycardia is a fast, abnormal heart rhythm that can be life-threatening, especially in people whose hearts are already damaged. Standard treatments include drugs, implanted defibrillators, and catheter ablation, but some frail patients cannot safely undergo ablation. This small trial tests whether stereotactic ablative radiotherapy, a precise form of high-dose radiation, can reduce episodes of ventricular tachycardia and improve quality of life in adults who have not responded to other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic ablative radiotherapy, a precisely targeted form of high-dose radiation
What this could lead to
If it works, radiotherapy could offer a non-invasive option for people with dangerous heart rhythms who are too frail for catheter ablation.
What could go wrong
This is a very small study of four people, so results may not apply broadly. Radiation near the heart carries risks of inflammation or damage to surrounding tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4 people

The number who actually took part.

Started

Jan 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. They are at least 18-85 years old. 2. They have recurrent VT (at least three episodes in the preceding six months) requiring therapy from an ICD, that is refractory to conventional treatments - both maximally tolerated doses of anti- arrhythmic drugs and/or conventional catheter ablation. 3. They are too frail or do not wish to undergo conventional catheter ablation. 4. They have not had previous radiotherapy to the anticipated treatment field. Exclusion Criteria: 1. They have polymorphic VT or ventricular fibrillation (VF). 2. They have inotrope-dependent heart failure or a left ventricular assist device (LVAD) in situ. 3. They are unlikely to live more than 12 months irrespective of the VT. 4. There is a potentially reversible cause for the VT e.g. critical coronary artery disease or a metabolic problem such as an overactive thyroid gland. 5. They are unable to provide informed consent. 6. They have had previous radiotherapy to the anticipated treatment field. 7. The patient weighs in excess of 170kg (maximum weight capacity of the tables in the imaging department).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Radiotherapy; complications Structural heart abnormality Ventricular tachycardia

Contacts and locations

Locations

  • St Bartholomew's Hospital

    London, EC1A 7BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.